Clinical Trial Detail

NCT ID NCT03206047
Title Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Recruitment Suspended
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

peritoneal carcinoma

fallopian tube carcinoma

ovary epithelial cancer

Therapies

Atezolizumab + Guadecitabine

Atezolizumab

Atezolizumab + Guadecitabine + Rasdegafusp alfa

Age Groups: adult senior

No variant requirements are available.